Cerus: revenue up 10%, adjusted EBITDA stays positive, RedeS hits main endpoint
Cerus reported a 10% rise in third-quarter product revenue and said RedeS met its primary efficacy endpoint. FY 2026 product revenue guidance was reaffirmed.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Cerus posted third-quarter product revenue up 10% year over year, according to TradingView. Adjusted EBITDA stayed positive for a 10th consecutive quarter, and operating cash flow came in at $3 million.
The company also said the RedeS study met its primary efficacy endpoint. Its FY 2026 product revenue guidance was reaffirmed at $229 million to $231 million.
why it matters
Investors will focus on three points: revenue growth, positive adjusted profitability and an unchanged annual outlook. The reaffirmed range gives a reference point for judging the company's next reports. The news concerns a single company, so its impact on the broader market is limited.
market impact
CERS: revenue growth and reaffirmed guidance support interest in the company's shares
tags
instruments
sources
- CERS: Revenue rose 10%, adjusted EBITDA stayed positive, and RedeS met its primary efficacy endpoint — TradingView, 2 November 2026 at 23:19 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗